Recombinant Human IL5RA protein, hFc-tagged

• Cat.No.: IL5RA-6744H
• Product Overview: Recombinant Human IL5RA protein(Q01344-1)(Asp21-Glu335), fused with C-terminal hFc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: C-hFc
• Protein length: Asp21-Glu335
• Form: Supplied as 0.22μm filtered solution in PBS (pH 7.4).
• Bio-activity: Immobilized Human IL-5, His Tag at 1ug/ml (100ul/Well) on the plate. Dose response curve for Human IL-5 R alpha, hFc Tag with the EC50 of 11.7ng/ml determined by ELISA.
• Molecular Mass: The protein has a predicted MW of 62.6 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.
• Endotoxin: Less than 1EU per μg by the LAL method.
• Purity: > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
• Storage: Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please do not repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: IL5RA interleukin 5 receptor, alpha [ Homo sapiens ]
• Official Symbol: IL5RA
• Synonyms: IL5RA; interleukin 5 receptor, alpha; IL5R; interleukin-5 receptor subunit alpha; CD125; CDw125; CD125 antigen; IL-5R subunit alpha; IL-5 receptor subunit alpha; interleukin 5 receptor type 3; interleukin-5 receptor alpha chain; HSIL5R3; MGC26560
• Gene ID: 3568
• mRNA Refseq: NM_000564
• Protein Refseq: NP_000555
• MIM: 147851
• UniProt ID: Q01344

Reviews

04/05/2021

Good stability under different temperature and humidity conditions.

03/27/2021

In the process of purification, the removal of impurities is good.

11/13/2020

Chemical modifications, such as PEGylation or glycosylation, have little effect.

Q&As

What are the clinical applications of IL5RA?

Recombinant IL5RA can be used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. It can reduce the frequency and severity of asthma attacks by blocking the signaling of interleukin 5.

Can recombinant IL5RA be used to treat other diseases?

Currently, recombinant IL5RA is mainly used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. For other diseases, the suitability of IL5RA is subject to further research and clinical trials.

Does the use of IL5RA require blood routine examination?

During the use of IL5RA, the doctor may ask to check the patient's blood routine regularly to monitor changes in blood counts and related indicators. This helps to evaluate the efficacy of the treatment and the safety of the patient.

Does IL5RA cause dependence?

There is no clear evidence that long-term use of recombinant IL5RA causes dependence. For patients using IL5RA, it is best to treat and discontinue the drug according to the advice and guidance of their doctor.

What is the use of IL5RA?

IL5RA is generally administered by subcutaneous injection. The specific use method and dosage should be determined according to the doctor's recommendation and the specific situation of the patient.

What are the side effects of IL5RA?

Common side effects of recombinant IL5RA include pain at the injection site, redness and swelling at the injection site, cough, and sore throat. A small number of patients may experience allergic reactions or serious adverse reactions, so close monitoring of the patient's condition and signs is required when using.